332 related articles for article (PubMed ID: 23801081)
21. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas.
Ren F; Zhao Q; Huang L; Zheng Y; Li L; He Q; Zhang C; Li F; Maimela NR; Sun Z; Jia Q; Ping Y; Zhang Z; Chen X; Yue Y; Liu S; Cao L; Zhang Y
Immunol Cell Biol; 2019 May; 97(5):457-469. PubMed ID: 30575118
[TBL] [Abstract][Full Text] [Related]
22. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
23. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
[TBL] [Abstract][Full Text] [Related]
24. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
[TBL] [Abstract][Full Text] [Related]
25. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
26. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.
Esmaeili M; Hamans BC; Navis AC; van Horssen R; Bathen TF; Gribbestad IS; Leenders WP; Heerschap A
Cancer Res; 2014 Sep; 74(17):4898-907. PubMed ID: 25005896
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
[TBL] [Abstract][Full Text] [Related]
28. IDH1
Kim GH; Choi SY; Oh TI; Kan SY; Kang H; Lee S; Oh T; Ko HM; Lim JH
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151327
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
Ma T; Zou F; Pusch S; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
Bioorg Med Chem; 2017 Dec; 25(24):6379-6387. PubMed ID: 29089260
[TBL] [Abstract][Full Text] [Related]
30. Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
Tiburcio PDB; Xiao B; Berg S; Asper S; Lyne S; Zhang Y; Zhu X; Yan H; Huang LE
Acta Neuropathol; 2018 Feb; 135(2):285-298. PubMed ID: 29288440
[TBL] [Abstract][Full Text] [Related]
31. Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer.
Li J; Huang J; Huang F; Jin Q; Zhu H; Wang X; Chen M
Oncotarget; 2016 Nov; 7(45):73638-73650. PubMed ID: 27655638
[TBL] [Abstract][Full Text] [Related]
32. Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations.
Kaneko MK; Tsujimoto Y; Hozumi Y; Goto K; Kato Y
Monoclon Antib Immunodiagn Immunother; 2013 Jun; 32(3):224-8. PubMed ID: 23750482
[TBL] [Abstract][Full Text] [Related]
33. Novel Insights for Inhibiting Mutant Heterodimer IDH1
Juritz EI; Bascur JP; Almonacid DE; González-Nilo FD
Mol Diagn Ther; 2018 Jun; 22(3):369-380. PubMed ID: 29651790
[TBL] [Abstract][Full Text] [Related]
34. Extracellular glutamate and IDH1
Tiburcio PDB; Gillespie DL; Jensen RL; Huang LE
J Neurooncol; 2020 Feb; 146(3):427-437. PubMed ID: 32020473
[TBL] [Abstract][Full Text] [Related]
35. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
36. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.
Ma D; Zhan D; Fu Y; Wei S; Lal B; Wang J; Li Y; Lopez-Bertoni H; Yalcin F; Dzaye O; Eberhart CG; Laterra J; Wilson MA; Ying M; Xia S
Cancer Lett; 2021 Oct; 517():35-45. PubMed ID: 34098063
[TBL] [Abstract][Full Text] [Related]
37. Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Stojković S; Podolski-Renić A; Dinić J; Stanković T; Banković J; Hadžić S; Paunović V; Isaković A; Tanić N; Pešić M
Exp Cell Res; 2015 Jul; 335(2):248-57. PubMed ID: 26026740
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
[TBL] [Abstract][Full Text] [Related]
39. An R132H mutation in isocitrate dehydrogenase 1 enhances p21 expression and inhibits phosphorylation of retinoblastoma protein in glioma cells.
Miyata S; Urabe M; Gomi A; Nagai M; Yamaguchi T; Tsukahara T; Mizukami H; Kume A; Ozawa K; Watanabe E
Neurol Med Chir (Tokyo); 2013; 53(10):645-54. PubMed ID: 24077277
[TBL] [Abstract][Full Text] [Related]
40. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
Sesanto R; Kuehn JF; Barber DL; White KA
Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
